Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stable isotope labeled levothyroxine refers to synthetic levothyroxine (L-thyroxine, T4) in which one or more atoms have been replaced with non-radioactive heavy isotopes such as carbon-13 (^13C) or deuterium (^2H/d3)[1][2][10]. These compounds are chemically and pharmacologically identical to regular levothyroxine but can be distinguished from endogenous hormone using mass spectrometry. They are primarily used as tracers in pharmacokinetic studies to precisely measure absorption, distribution, metabolism, and elimination of exogenous T4 without interference from the body’s own hormone[1][3]. The mechanism of action is identical to standard levothyroxine—acting as a replacement for deficient thyroxine by binding thyroid hormone receptors and regulating gene expression involved in metabolic processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stable isotope labeled levothyroxine.